Investigation of L-Carnitine Concentrations in Treated Patients with Maple Syrup Urine Disease
Abstract Maple syrup urine disease (MSUD), also known as branched-chain α ketoaciduria, is a metabolic disorder caused by an inborn deficiency in the activity of the branched-chain α-ketoacid dehydrogenase complex. Severe neurological damage occurs in most patients with MSUD although the exact mecha...
Gespeichert in:
Veröffentlicht in: | Journal of pediatric genetics (Birmingham, Ala.) Ala.), 2019-09, Vol.8 (3), p.133-136 |
---|---|
Hauptverfasser: | , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 136 |
---|---|
container_issue | 3 |
container_start_page | 133 |
container_title | Journal of pediatric genetics (Birmingham, Ala.) |
container_volume | 8 |
creator | Kumru, Burcu Oztürk Hismi, Burcu |
description | Abstract
Maple syrup urine disease (MSUD), also known as branched-chain α ketoaciduria, is a metabolic disorder caused by an inborn deficiency in the activity of the branched-chain α-ketoacid dehydrogenase complex. Severe neurological damage occurs in most patients with MSUD although the exact mechanism of neurotoxicity still remains unknown. Studies have suggested that neuropathology in patients with MSUD may be related to oxidative stress. L
-
carnitine mediates the transport of fatty acids into the mitochondria that are required for β-oxidation and ATP production. Along with the important roles it plays in lipid metabolism, L-carnitine also protects tissues from oxidative damage through its antioxidant properties. The study included a total of 15 patients with MSUD who attended regular follow-up visits, and 15 age-matched healthy control subjects, and aimed to investigate L
-
carnitine levels in treated patients with MSUD and healthy control subjects. L
-
carnitine levels were found to be significantly lower in the patient group than in the healthy controls. No significant correlation was identified between the plasma branched-chain amino acids leucine, isoleucine, valine, and L
-
carnitine levels. Patients with MSUD can be treated with adjuvant therapy with L
-
carnitine supplementation. |
doi_str_mv | 10.1055/s-0039-1691789 |
format | Article |
fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6688891</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>31406618</sourcerecordid><originalsourceid>FETCH-LOGICAL-c358t-44fbdcccf2f34fd62f69d6f9baadf0226bba2278f7d80523161bcc0a58fdb8393</originalsourceid><addsrcrecordid>eNp1kE1LwzAYx4MobsxdPUq-QDVJ2zS5CFLfBhMFN_BkSJtky9jSknSTfXs7uw09mMsT8n_Jww-AS4yuMUrTmxAhFPMIU44zxk9An-CERglFH6eHe8ppDwxDWKD2ZDgmnJ2DXowTRClmffA5chsdGjuTja0crAwcR7n0zjbWaZhXrtSu8T9igNbBidey0Qq-tU-tEuCXbebwRdZLDd-3fl3Dqd8l723QMugLcGbkMujhfg7A9PFhkj9H49enUX43jso4ZU2UJKZQZVkaYuLEKEoM5YoaXkipDCKEFoUkJGMmUwylJMYUF2WJZMqMKljM4wG47XrrdbHSqlt6KWpvV9JvRSWt-Ks4OxezaiMoZYxx3BZcdwWlr0Lw2hyzGIkdbBHEDrbYw24DV79_PNoPaFtD1BmaudUrLRbV2ruWwX-F35Lfi4Q</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Investigation of L-Carnitine Concentrations in Treated Patients with Maple Syrup Urine Disease</title><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Kumru, Burcu ; Oztürk Hismi, Burcu</creator><creatorcontrib>Kumru, Burcu ; Oztürk Hismi, Burcu</creatorcontrib><description>Abstract
Maple syrup urine disease (MSUD), also known as branched-chain α ketoaciduria, is a metabolic disorder caused by an inborn deficiency in the activity of the branched-chain α-ketoacid dehydrogenase complex. Severe neurological damage occurs in most patients with MSUD although the exact mechanism of neurotoxicity still remains unknown. Studies have suggested that neuropathology in patients with MSUD may be related to oxidative stress. L
-
carnitine mediates the transport of fatty acids into the mitochondria that are required for β-oxidation and ATP production. Along with the important roles it plays in lipid metabolism, L-carnitine also protects tissues from oxidative damage through its antioxidant properties. The study included a total of 15 patients with MSUD who attended regular follow-up visits, and 15 age-matched healthy control subjects, and aimed to investigate L
-
carnitine levels in treated patients with MSUD and healthy control subjects. L
-
carnitine levels were found to be significantly lower in the patient group than in the healthy controls. No significant correlation was identified between the plasma branched-chain amino acids leucine, isoleucine, valine, and L
-
carnitine levels. Patients with MSUD can be treated with adjuvant therapy with L
-
carnitine supplementation.</description><identifier>ISSN: 2146-4596</identifier><identifier>EISSN: 2146-460X</identifier><identifier>DOI: 10.1055/s-0039-1691789</identifier><identifier>PMID: 31406618</identifier><language>eng</language><publisher>Stuttgart · New York: Georg Thieme Verlag KG</publisher><subject>Original ; Original Article</subject><ispartof>Journal of pediatric genetics (Birmingham, Ala.), 2019-09, Vol.8 (3), p.133-136</ispartof><rights>Thieme Medical Publishers</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c358t-44fbdcccf2f34fd62f69d6f9baadf0226bba2278f7d80523161bcc0a58fdb8393</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6688891/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6688891/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31406618$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kumru, Burcu</creatorcontrib><creatorcontrib>Oztürk Hismi, Burcu</creatorcontrib><title>Investigation of L-Carnitine Concentrations in Treated Patients with Maple Syrup Urine Disease</title><title>Journal of pediatric genetics (Birmingham, Ala.)</title><addtitle>J Pediatr Genet</addtitle><description>Abstract
Maple syrup urine disease (MSUD), also known as branched-chain α ketoaciduria, is a metabolic disorder caused by an inborn deficiency in the activity of the branched-chain α-ketoacid dehydrogenase complex. Severe neurological damage occurs in most patients with MSUD although the exact mechanism of neurotoxicity still remains unknown. Studies have suggested that neuropathology in patients with MSUD may be related to oxidative stress. L
-
carnitine mediates the transport of fatty acids into the mitochondria that are required for β-oxidation and ATP production. Along with the important roles it plays in lipid metabolism, L-carnitine also protects tissues from oxidative damage through its antioxidant properties. The study included a total of 15 patients with MSUD who attended regular follow-up visits, and 15 age-matched healthy control subjects, and aimed to investigate L
-
carnitine levels in treated patients with MSUD and healthy control subjects. L
-
carnitine levels were found to be significantly lower in the patient group than in the healthy controls. No significant correlation was identified between the plasma branched-chain amino acids leucine, isoleucine, valine, and L
-
carnitine levels. Patients with MSUD can be treated with adjuvant therapy with L
-
carnitine supplementation.</description><subject>Original</subject><subject>Original Article</subject><issn>2146-4596</issn><issn>2146-460X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNp1kE1LwzAYx4MobsxdPUq-QDVJ2zS5CFLfBhMFN_BkSJtky9jSknSTfXs7uw09mMsT8n_Jww-AS4yuMUrTmxAhFPMIU44zxk9An-CERglFH6eHe8ppDwxDWKD2ZDgmnJ2DXowTRClmffA5chsdGjuTja0crAwcR7n0zjbWaZhXrtSu8T9igNbBidey0Qq-tU-tEuCXbebwRdZLDd-3fl3Dqd8l723QMugLcGbkMujhfg7A9PFhkj9H49enUX43jso4ZU2UJKZQZVkaYuLEKEoM5YoaXkipDCKEFoUkJGMmUwylJMYUF2WJZMqMKljM4wG47XrrdbHSqlt6KWpvV9JvRSWt-Ks4OxezaiMoZYxx3BZcdwWlr0Lw2hyzGIkdbBHEDrbYw24DV79_PNoPaFtD1BmaudUrLRbV2ruWwX-F35Lfi4Q</recordid><startdate>20190901</startdate><enddate>20190901</enddate><creator>Kumru, Burcu</creator><creator>Oztürk Hismi, Burcu</creator><general>Georg Thieme Verlag KG</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20190901</creationdate><title>Investigation of L-Carnitine Concentrations in Treated Patients with Maple Syrup Urine Disease</title><author>Kumru, Burcu ; Oztürk Hismi, Burcu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c358t-44fbdcccf2f34fd62f69d6f9baadf0226bba2278f7d80523161bcc0a58fdb8393</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Original</topic><topic>Original Article</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kumru, Burcu</creatorcontrib><creatorcontrib>Oztürk Hismi, Burcu</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of pediatric genetics (Birmingham, Ala.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kumru, Burcu</au><au>Oztürk Hismi, Burcu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Investigation of L-Carnitine Concentrations in Treated Patients with Maple Syrup Urine Disease</atitle><jtitle>Journal of pediatric genetics (Birmingham, Ala.)</jtitle><addtitle>J Pediatr Genet</addtitle><date>2019-09-01</date><risdate>2019</risdate><volume>8</volume><issue>3</issue><spage>133</spage><epage>136</epage><pages>133-136</pages><issn>2146-4596</issn><eissn>2146-460X</eissn><abstract>Abstract
Maple syrup urine disease (MSUD), also known as branched-chain α ketoaciduria, is a metabolic disorder caused by an inborn deficiency in the activity of the branched-chain α-ketoacid dehydrogenase complex. Severe neurological damage occurs in most patients with MSUD although the exact mechanism of neurotoxicity still remains unknown. Studies have suggested that neuropathology in patients with MSUD may be related to oxidative stress. L
-
carnitine mediates the transport of fatty acids into the mitochondria that are required for β-oxidation and ATP production. Along with the important roles it plays in lipid metabolism, L-carnitine also protects tissues from oxidative damage through its antioxidant properties. The study included a total of 15 patients with MSUD who attended regular follow-up visits, and 15 age-matched healthy control subjects, and aimed to investigate L
-
carnitine levels in treated patients with MSUD and healthy control subjects. L
-
carnitine levels were found to be significantly lower in the patient group than in the healthy controls. No significant correlation was identified between the plasma branched-chain amino acids leucine, isoleucine, valine, and L
-
carnitine levels. Patients with MSUD can be treated with adjuvant therapy with L
-
carnitine supplementation.</abstract><cop>Stuttgart · New York</cop><pub>Georg Thieme Verlag KG</pub><pmid>31406618</pmid><doi>10.1055/s-0039-1691789</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2146-4596 |
ispartof | Journal of pediatric genetics (Birmingham, Ala.), 2019-09, Vol.8 (3), p.133-136 |
issn | 2146-4596 2146-460X |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6688891 |
source | EZB-FREE-00999 freely available EZB journals; PubMed Central |
subjects | Original Original Article |
title | Investigation of L-Carnitine Concentrations in Treated Patients with Maple Syrup Urine Disease |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T11%3A54%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Investigation%20of%20L-Carnitine%20Concentrations%20in%20Treated%20Patients%20with%20Maple%20Syrup%20Urine%20Disease&rft.jtitle=Journal%20of%20pediatric%20genetics%20(Birmingham,%20Ala.)&rft.au=Kumru,%20Burcu&rft.date=2019-09-01&rft.volume=8&rft.issue=3&rft.spage=133&rft.epage=136&rft.pages=133-136&rft.issn=2146-4596&rft.eissn=2146-460X&rft_id=info:doi/10.1055/s-0039-1691789&rft_dat=%3Cpubmed_cross%3E31406618%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/31406618&rfr_iscdi=true |